Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Epeius Biotechnologies, a developer of tumor-targeted gene delivery systems, has received two additional European patents for the platform targeting technologies and molecular designs that enable precision gene delivery to primary cancers and metastatic lesions that have spread throughout the body.
Subscribe to our email newsletter
These latest EU patents follow on the heels of a major clinical patent that was recently awarded in the US for targeted gene delivery in vivo. Together these clinical patents provide additional intellectual property protection for advanced biotechnologies platform embodied in the company’s anticancer agent Rexin-G – the first and so far only tumor-targeted gene delivery system that has been successfully validated in the clinic.
Rexin-G is commercially available in the Philippines – for use in all solid tumors that are refractory to standard chemotherapy – and is currently in clinical trials in the US for several types of cancer.